NYSE:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $0.30 +0.00 (+1.38%) (As of 04:10 PM ET) Add Compare Share Share Today's Range$0.29▼$0.3150-Day Range$0.26▼$0.4252-Week Range$0.25▼$0.62Volume130,335 shsAverage Volume236,296 shsMarket Capitalization$15.50 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get AIM ImmunoTech alerts: Email Address Ad Market JARBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a shooter's exact location.Don't miss out. Get the full details on this AI bargain. About AIM ImmunoTech Stock (NYSE:AIM)AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Read More AIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIM Stock News HeadlinesAugust 20, 2024 | globenewswire.comAIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchAugust 17, 2024 | msn.comAIM ImmunoTech Inc. (AMEX:AIM) Q2 2024 Earnings Call TranscriptSeptember 16, 2024 | Brownstone Research (Ad)Bill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.August 16, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 16, 2024 | seekingalpha.comAIM ImmunoTech Inc. (AIM) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | globenewswire.comAIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | uk.finance.yahoo.comSamson Rock Capital LLP - Form 8.3 - Trident Royalties PlcAugust 13, 2024 | msn.comJim Click's 2006 Ford Mustang FR500C Race Car Hits Bring a Trailer AuctionSeptember 16, 2024 | Brownstone Research (Ad)Bill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.August 13, 2024 | msn.com535p?! This broker just hiked the forecast for the Rolls-Royce share priceAugust 13, 2024 | globenewswire.comAIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and WebcastJuly 29, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentJuly 25, 2024 | finance.yahoo.comAIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination TherapyJuly 24, 2024 | globenewswire.comAIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination TherapyJuly 3, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentJune 10, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Pitch ConferenceJune 3, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break SeriesMay 31, 2024 | globenewswire.comAIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct OfferingSee More Headlines Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees20Year Founded1990Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,533.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,960,000.00 Net Margins-13,952.74% Pretax Margin-13,952.74% Return on Equity-269.04% Return on Assets-141.74% Debt Debt-to-Equity Ratio0.05 Current Ratio1.17 Quick Ratio1.17 Sales & Book Value Annual Sales$201,000.00 Price / Sales78.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book1.53Miscellaneous Outstanding Shares51,496,000Free Float51,486,000Market Cap$15.76 million OptionableNot Optionable Beta-0.39 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Thomas K. Equels Esq. (Age 71)J.D., M.S., Executive Vice Chairman, CEO & President Comp: $953.19kMr. Robert Dickey IV (Age 68)M.B.A., Chief Financial Officer Comp: $64.48kMr. Peter W. Rodino III (Age 73)Esq., J.D., COO, Executive Director of Governmental Relations, General Counsel & Secretary Comp: $484.94kAnn Marie E. CoverlyDirector of Administration & Human Resources and Deputy Investor Relations CoordinatorDr. Carol A. Smith (Age 73)Chief Manufacturing Officer & Deputy Chief Scientific Officer Comp: $170.77kDr. Christopher McAleer Ph.D.Scientific OfficerDr. Ralph Christopher Cavalli Ph.D. (Age 66)Vice President of QC & Manufacturing Comp: $234.79kMore ExecutivesKey CompetitorsConnect BiopharmaNASDAQ:CNTBEntera BioNASDAQ:ENTXImunonNASDAQ:IMNNGritstone bioNASDAQ:GRTSAileron TherapeuticsNASDAQ:ALRNView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 4,078,000 shares on 8/15/2024Ownership: 7.919%Thomas K EquelsBought 61,729 shares on 5/6/2024Total: $25,308.89 ($0.41/share)Peter W Rodino IIIBought 30,865 shares on 5/6/2024Total: $12,654.65 ($0.41/share)Nancy BryanBought 38,462 shares on 3/21/2024Total: $15,000.18 ($0.39/share)Thomas K EquelsBought 75,758 shares on 3/15/2024Total: $25,000.14 ($0.33/share)View All Insider TransactionsView All Institutional Transactions AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $0.4399 at the beginning of the year. Since then, AIM shares have decreased by 33.2% and is now trading at $0.2937. View the best growth stocks for 2024 here. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. The firm earned $0.05 million during the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 269.04% and a negative net margin of 13,952.74%. When did AIM ImmunoTech's stock split? Shares of AIM ImmunoTech split before market open on Saturday, January 1st 2000. The 12-1 split was announced on Saturday, January 1st 2000. The newly minted shares were distributed to shareholders after the closing bell on Monday, August 29th 2016. An investor that had 100 shares of stock prior to the split would have 1,200 shares after the split. Who are AIM ImmunoTech's major shareholders? AIM ImmunoTech's top institutional shareholders include Armistice Capital LLC (7.92%). Insiders that own company stock include Thomas K Equels, Stewart Appelrouth, Peter W Rodino III and Nancy Bryan. View institutional ownership trends. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV) and T2 Biosystems (TTOO). This page (NYSE:AIM) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIM Stock Alerts